Edwards Lifesciences (NYSE:EW) VP Donald Bobo, Jr. Sells 23,145 Shares of Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 23,145 shares of the stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Edwards Lifesciences Stock Down 1.1%

Edwards Lifesciences stock opened at $86.55 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The stock has a market capitalization of $49.83 billion, a price-to-earnings ratio of 46.04, a PEG ratio of 2.19 and a beta of 0.87. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $88.28. The business has a fifty day moving average price of $81.62 and a 200-day moving average price of $82.97.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The firm had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the subject of several research analyst reports. UBS Group reaffirmed a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research report on Monday, April 13th. Robert W. Baird boosted their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Finally, Piper Sandler reissued an “overweight” rating and set a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $95.65.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds and other institutional investors have recently bought and sold shares of EW. Mirae Asset Global Investments Co. Ltd. boosted its position in Edwards Lifesciences by 13.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock worth $6,706,000 after purchasing an additional 10,078 shares in the last quarter. Atlantic Union Bankshares Corp boosted its position in Edwards Lifesciences by 2,240.9% during the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock worth $925,000 after purchasing an additional 11,384 shares in the last quarter. Washington Trust Advisors Inc. boosted its position in Edwards Lifesciences by 15.6% during the third quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock worth $10,156,000 after purchasing an additional 17,625 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Edwards Lifesciences by 8.1% during the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after purchasing an additional 1,423,365 shares in the last quarter. Finally, Azzad Asset Management Inc. ADV boosted its position in Edwards Lifesciences by 330.5% during the third quarter. Azzad Asset Management Inc. ADV now owns 21,227 shares of the medical research company’s stock worth $1,651,000 after purchasing an additional 16,296 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.